AzTrials
AzTrials

Coronary Artery Disease (CAD)Phase 3EXERRTNCT01618669

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

A Phase 3 study testing Regadenoson and Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in people with Coronary Artery Disease (CAD), run by Astellas Pharma Global Development, Inc. at 69 sites in 4 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with regadenoson alone is not inferior to the strength of agreement between two sequential… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Coronary Artery Disease (CAD)
What is being tested?
Regadenoson and Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,147 participants
Where
69 sitesin 4 countries
Study dates
Jun 2012to Dec 2014
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects referred for an exercise or pharmacologic stress test SPECT MPI procedure for the evaluation of coronary artery disease (CAD) are eligible for study participation. Subjects referred for pharmacologic stress should have a reasonable potential of attempting exercise stress. Subject must have one of the following:
  • a. Past ischemia on any prior imaging stress test without invasive intervention on the artery subtending this territory
  • b. Subject with known CAD who have symptoms similar to previous ischemic symptoms, or recent onset of symptoms or recently worsened symptoms suggestive of ischemia
  • c. Diamond Forrester estimated pretest probability of CAD of ≥ 50%
  • d. History of most recent coronary artery bypass surgery or most recent percutaneous coronary intervention (PCI) > 10 years (patients who are > 30 days but less than 10 years post coronary artery bypass graft (CABG) or PCI can be included if they meet criteria a, b, or e)
  • e. Previously demonstrated 100% occlusion by invasive coronary or computed tomography (CT) angiography without successful intervening revascularization as these foods may alter regadenoson effects

Who cannot join

  • Subject has a clinically significant illness, medical condition, or laboratory abnormality
  • Female subject who is pregnant or lactating
  • Subject is on dialysis for end stage renal disease or has a history of glomerular filtration rate (GFR) < 15 mL/min (calculated using MDRD [Modification of Diet in Renal Disease] formula)
  • Subject has a history of coronary revascularization by either PCI or CABG within 1 month prior to the rest myocardial perfusion imaging (MPI)
  • Subject has a pacemaker or an implantable cardioverter defibrillator (ICD)
  • Subject has a history of acute myocardial infarction (MI) or high risk unstable angina within 30 days prior to the rest MPI or has had cardiac transplantation
Show all 9Show fewer
  • Subject has uncontrolled hypertension at any point on Visit 2 prior to exercise testing (i.e., systolic blood pressure (SBP) ≥ 180 or diastolic blood pressure (DBP) ≥ 95 mmHg on two consecutive measurements while at rest).
  • Subject has severe aortic stenosis or hypertrophic cardiomyopathy with obstruction or has decompensated congestive heart failure
  • Subject has a history of severe respiratory disease including: asthma, chronic obstructive pulmonary disease (COPD) or other bronchospastic reactive airway disease or who is on 24-hour continuous oxygen

Trial locations and contacts

69 sites in 4 countries.

69 sites in 4 countries

United States60 sites
  • St. Joseph's Hospital

    Atlanta, Georgia, 30342

  • University Cardiology Associates, LLC

    Augusta, Georgia, 30901

  • Elite Research and Clinical Trials

    Aventura, Florida, 33180

  • University of Maryland

    Baltimore, Maryland, 21207

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114

  • University of Virginia

    Charlottesville, Virginia, 22908

  • Rush University Medical Center

    Chicago, Illinois, 60612

  • Henry Ford Hospital

    Detriot, Michigan, 48202

  • Wayne State University

    Detroit, Michigan, 48201

  • S & W Clinical Research

    Fort Lauderdale, Florida, 33306

  • Holy Cross Hospital

    Fort Lauderdale, Florida, 33308

  • Florida Heart Associates

    Fort Myers, Florida, 33907

  • Silicon Valley Medical Imaging

    Fremont, California, 94538

  • I U School of Medicine/ Krannert Institute of Cardiology

    Indianapolis, Indiana, 46202

  • East Coast Institute for Research, LLC

    Jacksonville, Florida, 32216

  • St. Luke's Cardiology St. Vincent's HealthCare

    Jacksonville, Florida, 32216

  • Cardiovascular Imaging Technologies

    Kansas City, Missouri, 64111

  • Katy Cardiology Associates

    Katy, Texas, 77493

  • Watson Medical Clinic/Lakeland Regional Medical Clinic

    Lakeland, Florida, 33805

  • Las Vegas Radiology

    Las Vegas, Nevada, 89113

  • Laurelton Medical center

    Laurelton, New York, 11422

  • Long Beach Memorial Medical Center

    Long Beach, California, 90806

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California, 90073

  • Westside Medical Associates of Los Angeles

    Los Angeles, California, 90211

  • Ventura Clinical Trials

    Malibu, California, 90265

  • MIMA Century Research Associates

    Melbourne, Florida, 32901

  • Cardiovascular Research Center of South Florida

    Miami, Florida, 33173

  • Hennepin County Medical Center

    Minneapolis, Minnesota, 55455

  • Mission Internal Medical Group

    Mission Viejo, California, 92691

  • Mobile Heart Specialists, PC

    Mobile, Alabama, 36608

  • Mission Research Institute LLC

    New Braunfels, Texas, 78130

  • HOCC - New Britain Campus

    New Britain, Connecticut, 06050

  • Yale University

    New Haven, Connecticut, 06510

  • Columbia University Medical Center

    New York, New York, 10032

  • Alfieri Cardiology

    Newark, Delaware, 19713

  • Alegent Health Heart and Vascular Specialists

    Omaha, Nebraska, 68124

  • Alegent Health Research Center

    Omaha, Nebraska, 68124

  • Florida Hospital/Cardiovascular Institute

    Orlando, Florida, 32803

  • Midwest Cardiology Associates

    Overland Park, Kansas, 66209

  • University of Pennsylvania Hospital

    Philadelphia, Pennsylvania, 19104

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213

  • Berkshire Medical Center

    Pittsfield, Massachusetts, 01201

  • Maine Research Associates

    Portland, Maine, 04210

  • Roanoke Heart Institute, PC

    Roanoke, Virginia, 24014

  • VA San Diego Healthcare System

    San Diego, California, 92161

  • Santa Rosa Cardiology Medical Group, Inc.

    Santa Rosa, California, 95405

  • South Coast Medical Group

    Savannah, Georgia, 31406

  • University of Washington

    Seattle, Washington, 98195

  • Washington University School of Medicine

    St Louis, Missouri, 63110

  • University of South Florida

    Tampa, Florida, 33620

  • West Houston Area Clinical Trial Consultants, LLC

    Tomball, Texas, 77375

  • Los Angeles Biomedical Research Institute

    Torrance, California, 22908

  • Cardiology Associates of North Mississippi

    Tupelo, Mississippi, 38801

  • Westchester Medical Center-New York Medical College

    Valhalla, New York, 10595

  • Cardiology Partners Clinical Research Institute

    Wellington, Florida, 33449

  • Buffalo Cardiology & Pulmonary Associates, P.C.

    Williamsville, New York, 14221

  • Delaware Clinical Trials

    Wilmington, Delaware, 19808

  • Berks Cardiologists, Ltd.

    Wyomissing, Pennsylvania, 19610

  • Michigan Heart

    Ypsilanti, Michigan, 48197

Other trials in United States

Argentina5 sites
  • Instituto Oulton

    Córdoba, X5000JJS

  • Instituto de Cardiologia la Plata

    La Plata, B1925XAC

  • Hospital Italiano de La Plata

    Provincia de Buenos Aires, B1900AX

  • Hospital Italiano Garibaldi

    Rosario, Santa Fe Province, S2000ODA

  • Sanatorio San Geronimo

    Santa Fe, S3001XAF

Other trials in Argentina

Peru3 sites
  • Clinica Anglo Americana

    Lima, Lima 27

  • Hospital Arzobispo Loayza

    Lima

  • Instituto Nacional Cardiovascular de EsSalud

    Lima

Other trials in Peru

Puerto Rico1 site
  • VA Caribbean Healthcare System (672)

    San Juan, 00921

Other trials in Puerto Rico

About this study

Official title: A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with regadenoson alone is not inferior to the strength of agreement between two sequential regadenoson SPECT images without exercise.

Being tested
Regadenoson, Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Keywords
Coronary Artery Disease (CAD), regadenoson, pharmacologic stress
Medical subject headings
Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RegadenosonDrug

    Also called Lexiscan, CVT3146

    Administered as an intravenous (IV) bolus

  • Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)Procedure or surgery

Study groups in NCT01618669
Study groupRoleWhat they receive
Regadenoson After Peak ExerciseExperimentalOn Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Receives: Drug: Regadenoson; Procedure: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Regadenoson AloneActive comparatorOn Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus (1 hour after exercise recovery), and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Receives: Drug: Regadenoson; Procedure: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans

    SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect.

    The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia.

    Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits.

    Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant.

    Measured: Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)

Secondary outcomes (11)
  1. Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events

    A clinically significant cardiac event is defined as:

    • Any of the following events found on the Holter electrocardiogram (ECG)/12-Lead ECG within 1 hour after regadenoson administration:
    • ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, ventricular flutter),
    • ST-T depression (> 2 mm),
    • ST-T elevation (≥1 mm),
    • Atrioventricular (AV) block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block)
    • sinus arrest > 3 seconds in duration

    Or

    • a treatment-emergent adverse event (TEAE) per the Medical Dictionary for Regulatory Activities (MedDRA) Standardised MedDRA Queries (SMQ) (Narrow Scope) for myocardial infarction

    Or

    • a TEAE preferred term of angina unstable within 24 hours of regadenoson administration.

    Measured: Within 1 hour for ECG events and up to 24 hours for adverse events after administration of regadenoson

  2. Proportion of Participants With Agreement in the Assessment of Absence or Presence of Ischemia Between First and Second Stress Scans

    The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as absence (0 to 1 reversible segments) or presence (≥ 2 reversible defects) of ischemia, the proportion of participants with agreement in the presence and absence of ischemia between the first and second stress scans was calculated.

    Measured: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)

  3. Proportion of Participants With Agreement in the Assessment of Reversible Defects in 3 Categories of Ischemia Between First and Second Stress Scans

    The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as 0 to 1, 2 to 4, or ≥ 5 reversible segments, the proportion of participants with agreement in the three ischemia categories between the first and second stress scans was to be calculated. In the reported data, these proportions only include the 0-1 and 2-4 categories; the ≥ 5 category was not included because there were no participants in this category for the Regadenoson Alone group for the initial stress MPI.

    Measured: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)

  4. Proportion of Participants With Agreement in the Summed Stress Score (SSS) Between First and Second Stress Scans

    The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. Each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:

    • 0: normal perfusion
    • 1: slightly reduced contrast/radiotracer uptake
    • 2: moderately reduced contrast/radiotracer uptake
    • 3: severely reduced contrast/radiotracer uptake
    • 4: absent contrast/radiotracer uptake.

    The Summed Stress Score (SSS) was calculated as the sum of the stress scores across the 17 segments. The mean value (rounded to the nearest integer) across the 3 readers was computed and the SSS was categorized into 4 group categorical variables based on the score: 0 to 3, 4 to 7, 8 to 11, and ≥ 12. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.

    Measured: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)

  5. Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans

    The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:

    • 0: normal perfusion
    • 1: slightly reduced contrast/ uptake
    • 2: moderately reduced contrast/uptake
    • 3: severely reduced contrast/uptake
    • 4: absent contrast/uptake.

    SSS was calculated as the sum of the stress scores across the 17 segments and the Summed Rest Score (SRS) was calculated as the sum of the rest scores across the 17 segments. The Summed Difference Score (SDS) is the difference in the SSS and SRS (SSS - SRS).

    The mean value (rounded to the nearest integer) across the 3 readers was computed and the SDS was categorized into 3 categorical variables based on the score: 0 to 6, 7 to 13 and ≥ 14. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.

    Measured: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)

  6. Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan

    Each reader evaluated the initial stress SPECT MPI scan compared to the participant's second stress SPECT MPI scan (blinded at time of the evaluation) for whether there was Less (-1), the Same (0) or More (1) reversible perfusion defects. The median assessment of the 3 blinded readers was used to summarize the number of participants in each category.

    Measured: Day 1 (stress MPI 1) and Day 2-15 (stress MPI 2)

  7. Overall Assessment of Image Quality

    The image quality for each scan was rated by each independent reader as 1 = Poor, 2 = Fair, 3 = Good, 4 = Excellent. Based on the median rating of overall image quality across the three readers, the number of participants with each rating is reported for each scan.

    Measured: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)

  8. Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans

    Image quality was assessed through radiotracer uptake in the heart (target organ) compared to liver, gut and combined liver plus gut (background interference).

    Measured: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)

  9. Percentage of Scans With Subdiaphragmatic Interference

    Each reader assessed the sub-diaphragmatic radiotracer interference with cardiac image quality using a 4-point scale of 0 = none, 1 = slight, 2 = moderate or 3 = severe for each stress SPECT MPI. The median rating across the 3 readers was used to summarize the percentage of scans with interference.

    Measured: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)

  10. Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity

    The number of cardiac segments obscured by the sub-diaphragmatic activity by group by stress SPECT MPI scan and by reader is reported.

    Measured: Day 1 (stress MPI 1) and Day - 15 (stress MPI 2)

  11. Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson

    An adverse event is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes:

    • Results in death,
    • Is life threatening,
    • Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions,
    • Results in congenital anomaly, or birth defect,
    • Requires inpatient hospitalization or leads to prolongation of hospitalization
    • Other medically important events.

    Relationship to study drug was assessed by the investigator.

    Measured: Up to 24 hours after study drug administration for each stress MPI (Day 1 and Day 2-15)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jun 2012 (estimated)
  2. Study startJun 2012
  3. Primary completionDec 2014
  4. Study completionDec 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,147 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01618669
Sponsor's protocol ID
3606-CL-3004
Acronym
EXERRT
Status last verified
Jan 2016
First submitted
29 May 2012
Last updated
8 Feb 2016
Data monitoring committee
No
Individual data sharing
Undecided

Publications

  • Thomas GS, Cullom SJ, Kitt TM, Feaheny KM, Ananthasubramaniam K, Gropler RJ, Jain D, Thompson RC. The EXERRT trial: "EXErcise to Regadenoson in Recovery Trial": A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol. J Nucl Cardiol. 2017 Jun;24(3):788-802. doi: 10.1007/s12350-017-0813-3. Epub 2017 Feb 21.

    PubMed 28224449

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Regadenoson and Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in people with Coronary Artery Disease (CAD), run by Astellas Pharma Global Development, Inc. at 69 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 69 sites in United States, Argentina, Peru, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Feb 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans (time frame: Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01618669, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in